UNSPSC 51151536: Ambenonium chloride

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C28H42Cl2N4O2.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51FOB87G3I, chemically known as n,n-bis(2-diethylaminoethyl)oxamide bis(2-chlorobenzyl chloride) but more generally known as ambenonium chloride, which bears US NIH Compound Identifier 8288. European Medicines Agency schedules Ambenonium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05394MIG.

UNSPSC 51151536 Ambenonium chloride is a Commodity code that shows limited recent state and local procurement activity directly aligned with its nominal scope. The two recent opportunities tagged under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—diverge significantly from the chemical pharmaceutical compound the code nominally describes. The Seminole County solicitation is a public health supply procurement (naloxone kits and drug disposal systems for community health initiatives), while the Texas HHS RFI addresses pharmacy benefit program contracting and prescription fulfillment logistics rather than ambenonium chloride acquisition. State and local issuing bodies engaging under this code include county health departments and state health and human services agencies, though the recent activity is sparse and the opportunities posted do not reflect procurement of the specific pharmaceutical chemical the code names.

Geographic activity centers on Florida and Texas based on the two recent postings. Seminole County, Florida issued an IFB on June 30, 2026 with a response deadline of July 26, 2026 (note: the posted date shows June 2026 but the underlying bid deadline cited is July 26, 2023, indicating a data inconsistency in the source) for quarterly deliveries of naloxone and drug deactivation systems totaling 1,900 units and 800 systems annually. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription contracting, with no formal response deadline or award structure defined at the exploratory stage. Neither opportunity reflects direct procurement of ambenonium chloride as a pharmaceutical input; the code appears to capture public health and pharmacy benefit management solicitations that are only tangentially related to its nominal scope, suggesting the code may see more activity under different categories or that state and local tagging practices do not align closely with the chemical pharmaceutical definition.